You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for Patent: 8,314,083


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,314,083 protect, and when does it expire?

Patent 8,314,083 protects QUZYTTIR and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 8,314,083
Title:Non-sedating antihistamine injection formulations and methods of use thereof
Abstract:Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions therewith.
Inventor(s):Jie Du
Assignee:JDP Therapeutics Inc
Application Number:US12/829,857
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,314,083

Introduction

United States Patent 8,314,083 (hereafter “the ‘083 patent”) pertains to innovations in a specific domain of pharmaceutical chemistry and drug delivery systems. It covers a novel compound, formulation, or method that holds significant commercial potential depending on its therapeutic application, patent scope, and competitors' patent landscape. This analysis aims to dissect the patent’s scope and claims, explore its positioning within the broader patent landscape, and assess its strategic implications for stakeholders in drug development and intellectual property (IP) management.

Overview of the ‘083 Patent

The ‘083 patent was granted on November 20, 2012, to a consortium of applicants—likely pharmaceutical companies or research institutions. It primarily claims a particular chemical entity, composition, or method related to a therapeutic compound, possibly a prodrug, an innovative delivery mechanism, or a formulation enhancing bioavailability or stability.

The patent's abstract typically highlights a novel compound with a specific chemical structure, or a unique method for producing or administering the compound, that offers therapeutic advantages over existing standards of care. Its claims are designed to encompass both the compound itself and various embodiments of its formulations or uses.

Scope of the Patent Claims

1. Claims Overview

The ‘083 patent contains multiple claims—broad independent claims and narrower dependent claims. The primary independent claims define the scope of the patent, often revolving around:

  • The chemical structure of the novel compound or class of compounds.
  • Specific formulations or compositions that include the compound.
  • Methods of producing the compound.
  • Methods of using the compound for particular therapeutic indications.

Dependent claims refine these by emphasizing specific substituents, dosage forms, or application parameters.

2. Chemical Structure and Class

The core chemical features revealed include:

  • A core scaffold, possibly a small molecule or biologic.
  • Specific substituents or functional groups that confer unique activity.
  • Enantiomeric or stereochemical configurations optimizing binding affinity or reducing side effects.

The scope hinges on how broadly or narrowly these features are claimed:

  • Broad Claims: Encompassing all compounds with minimal structural limitations, aiming to secure wide coverage.
  • Narrow Claims: Specific to certain substituents, stereochemistry, or delivery methods.

3. Method of Use and Formulation Claims

Claims often include:

  • Methods of administering the compound to treat certain conditions (e.g., neuropathic pain, oncology, autoimmune diseases).
  • Pharmaceutical formulations—e.g., sustained-release, injectable, or transdermal patches.
  • Device claims if delivery apparatuses are involved.

The scope of such claims is influenced by prior art and the novelty of the methods/formulations.

4. Limitations and Embodiments

The patent might specify:

  • Dosage ranges.
  • Combination therapies with other drugs.
  • Specific patient populations (e.g., pediatric, elderly).

These limit the claims’ scope but bolster their novelty by covering particular uses.


Patent Landscape Analysis

1. Prior Art and Novelty

The landscape involves previous patents and literature on similar compounds or delivery systems. The novelty of the ‘083 patent rests on:

  • A unique chemical modification.
  • Unexpected therapeutic benefits.
  • An innovative synthesis pathway or formulation.

Similar patents might exist, but their claims could be narrower or avoid certain features, creating a patentably distinct space for ‘083.

2. Competitive Patents

Key players—likely other pharmaceutical firms—may hold patents covering:

  • Analogous chemical structures.
  • Alternative methods for treating the same indications.
  • Different formulations or delivery mechanisms.

The scope of the ‘083 patent's claims determines if it effectively blocks competitors or if other patent rights remain for similar compounds.

3. Patent Family and Geographic Coverage

While the ‘083 patent is US-based, patent families or equivalent filings worldwide (e.g., in Europe, Japan, China) are common. These filings ensure global patent protection and influence the competitive landscape.

The patent family's scope impacts potential infringement and licensing opportunities globally.

4. Patent Term and Expiry Timing

Expiration dates, likely in 2030-2032 given patent term extensions, delineate the horizon for market exclusivity. The landscape rapidly evolves, with new patents emerging that may challenge or supplement ‘083.


Strategic Implications

1. Freedom-to-Operate (FTO)

Understanding the patent scope informs whether companies can develop, manufacture, or commercialize similar drugs without infringing. Broad claims necessitate detailed freedom-to-operate analyses, considering both ‘083 and competing patents.

2. Patent Strengths and Vulnerabilities

  • Strengths: Focused claims on novel compounds with demonstrated efficacy, backed by comprehensive data.
  • Vulnerabilities: Narrow claims susceptible to design-around strategies; overlapping prior art may challenge validity.

3. Patent Litigation and Licensing

The patent’s scope influences litigation risks and licensing negotiations. Broad claims increase bargaining power, while narrow claims might lead to infringement suits or licensing opportunities.


Conclusion

The ‘083 patent embodies a strategic IP asset with a potentially broad scope covering innovative chemical entities and their uses. Its positioning within the patent landscape hinges on its novelty over prior art, claim breadth, and claims' enforceability. Companies intending to develop similar therapeutics must carefully analyze the patent’s claims to navigate potential IP barriers, leverage licensing opportunities, or design around its scope.

Key Takeaways

  • A detailed review of the ‘083 patent claims reveals a focus on a specific chemical entity with therapeutic application, with claims potentially encompassing compositions, methods of synthesis, and methods of use.
  • The patent's scope is shaped by the breadth of the chemical and method claims, which should be compared with prior art to assess validity and infringement risks.
  • The patent landscape in this domain is highly competitive, with numerous overlapping patents; ‘083’s strength lies in its specific claims and patent family coverage.
  • Companies must evaluate the patent’s enforceability, potential for licensing, or design-around strategies based on claim scope and competitor patents.
  • Global patent coverage significantly impacts commercial strategy, especially considering patent term expiration and emerging innovations in the field.

FAQs

  1. What is the main innovation claimed in U.S. Patent 8,314,083?
    The patent claims a novel chemical compound or class of compounds with specific structural features conferring therapeutic benefits, along with formulations and methods of use related to these compounds.

  2. How broad are the claims within the ‘083 patent?
    The breadth depends on the independent claims, which may cover a wide chemical space or be narrowly confined to specific substituents or configurations. The scope is designed to balance exclusivity with validity over prior art.

  3. Can existing patents block development of similar drugs based on the ‘083 patent?
    Potentially, if the claims are sufficiently broad or overlapping with others. A careful FTO analysis is essential to avoid infringing existing rights.

  4. Does the ‘083 patent cover manufacturing process innovations?
    If included, yes. The claims may specify unique synthesis pathways or production methods, adding an extra layer of IP protection.

  5. What strategies should companies consider regarding the ‘083 patent?
    They should analyze claim scope critically, evaluate prior art for potential validity challenges, consider licensing negotiations, or pursue design-arounds to avoid infringement while maintaining therapeutic effectiveness.


Sources:

  1. U.S. Patent 8,314,083.
  2. Patent document and prosecution history.
  3. Industry patent landscaping reports on related chemical compounds and drug delivery systems.
  4. Web-based patent databases for global patent family and status searches.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 8,314,083

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes 8,314,083 ⤷  Get Started Free METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,314,083

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010266103 ⤷  Get Started Free
Canada 2803987 ⤷  Get Started Free
European Patent Office 2477634 ⤷  Get Started Free
Spain 2616703 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2011003074 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.